Valuation: Black Diamond Therapeutics, Inc.

Market Cap 115M 101M 92.53M 86.25M 164M 10.97B 166M 1.11B 432M 5.39B 432M 423M 18.58B P/E 2026 *
-3.1x
P/E 2027 * -2x
Enterprise Value 115M 101M 92.53M 86.25M 164M 10.97B 166M 1.11B 432M 5.39B 432M 423M 18.58B EV / Sales 2026 *
20.7x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
1 day+9.24%
1 week+17.54%
Current month+8.65%
1 month+2.03%
3 months-15.90%
6 months-21.79%
Current year-17.28%
1 week 1.74
Extreme 1.745
2.04
1 month 1.6
Extreme 1.6
2.04
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
12
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 16/09/2023
Chief Tech/Sci/R&D Officer 51 11/08/2021
Director of Finance/CFO 41 07/10/2024
Director TitleAgeSince
Director/Board Member 61 01/03/2017
Director/Board Member 47 01/12/2019
Director/Board Member 50 01/12/2018
Date Insider Type Main position Quantity % Market Cap.
26/06Free

Director

40,000 0.0698%
26/06Free

Director

40,000 0.0698%
26/06Free

Director

40,000 0.0698%
Change 5-day change 1-year change 3-year change Capi.($)
+9.24%+17.54%-22.09%-58.64% 115M
-0.43%+5.32%+77.55%+135.13% 59.1B
+2.32%+5.03%+75.26%+92.31% 55.19B
+3.86%+6.93%-11.32%-10.57% 24.67B
+4.30%+7.95%+14.11%+440.44% 24.19B
+0.64%+7.14%+50.90%-1.05% 19.69B
-1.34%+7.48%+41.21%-28.85% 17.56B
0.00%+20.78%+186.15%+347.42% 16.22B
+4.91%+20.18%+48.55% - 14.84B
+3.50%+1.97%+21.02%+193.33% 14.04B
Average +2.70%+9.53%+48.13%+123.28% 24.56B
Weighted average by Cap. +1.69%+6.48%+59.27%+135.59%

Financials

2026 *2027 *
Net sales 5.56M 4.86M 4.46M 4.16M 7.89M 529M 8.01M 53.58M 20.83M 260M 20.85M 20.41M 896M -
Net income -40.47M -35.38M -32.52M -30.31M -57.49M -3.85B -58.36M -390M -152M -1.89B -152M -149M -6.53B -70.04M -61.23M -56.27M -52.45M -99.49M -6.67B -101M -676M -263M -3.28B -263M -257M -11.3B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
02/07/26 USD 2.010 +9.24% 1,577,070
01/07/26 USD 1.840 -0.54% 4,375,137
30/06/26 USD 1.850 +5.71% 1,883,436
29/06/26 USD 1.750 +2.34% 1,154,453
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
2.010USD
Average target price
9.857USD
Spread / Average Target
+390.40%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock